N-PVP (alpha-Pyrrolidinohexiophenone congener)
N-PVP is a pyrrolidinophenone-class designer cathinone closely related to alpha-PVP, appearing on grey-market listings as a stimulant reuptake inhibitor. Human data is effectively nonexistent; risk is inferred from the well-documented toxicity of its parent alpha-PVP.
01 Overview
N-PVP belongs to the same pyrrolidinophenone lineage that produced alpha-PVP ('flakka'), a cathinone notorious for excited-delirium presentations. It is sold as powder or crystal for insufflation or vaporisation.
There are no clinical pharmacokinetic or safety studies. Assessment relies on forensic identification and read-across from alpha-PVP, which strongly predicts potent stimulant effects, compulsive use and dangerous sympathomimetic and psychiatric toxicity.
02 Mechanism
Presumed potent norepinephrine-dopamine reuptake inhibitor, consistent with the pyrrolidinophenone pharmacophore.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common (approximate, anecdotal) | 5–15 mg | Insufflated | No validated dosing; extreme caution given alpha-PVP-like potency. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Intense stimulationExpected marked energy and euphoria by analogy to alpha-PVP; not verified in humans. | Presumed strong | Unconfirmed | |
| Craving and compulsionPyrrolidinophenones characteristically drive binge redosing. | Presumed strong | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Cardiovascular strainTachycardia, hypertension and arrhythmia expected by class analogy. | Severe | Unknown | Unconfirmed | |
| Excited delirium / severe agitationalpha-PVP is associated with agitated delirium, hyperthermia and death; N-PVP risk is presumed similar. | Life-threatening | Unknown; documented for parent alpha-PVP | Unconfirmed |